Short answer
Nurix Therapeutics, Inc. (NRIX) filed an 8-K current report with the SEC on June 11, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Nurix disclosed updated Phase 1a/1b clinical data for BTK degrader bexobrutideg (NX-5948).
Nurix Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Nurix disclosed updated Phase 1a/1b clinical data for BTK degrader bexobrutideg (NX-5948)
- Data covers patients with relapsed or refractory CLL and SLL
- Results scheduled for presentation at EHA2026, potentially informing the drug’s clinical development trajectory
- Full efficacy and safety findings contained in Exhibit 99.1keletal
Item 8.01 · Other Events
- Phase 1a/1b safety population: 142 CLL/SLL patients, including 86 at 600 mg RP2D; no dose-limiting toxicities
- Phase 1a ORR 83.0% after 22.4-month median follow-up, with median progression-free survival of 22.1 months
- Responses observed despite BTK resistance mutations, high-risk features and CNS involvement, supporting activity in difficult-to-treat disease
- Earlier-line Cohort 5: 92.9% ORR among 14 evaluable patients, with 18 of 19 remaining on treatment
- BTKi-naïve Cohort 15: 84.2% ORR among 19 evaluable patients, including 10 treatment-naïve patients
Item EX-99.1 · Exhibit EX-99.1
- Updated Phase 1 data supports bexobrutideg’s potential across CLL treatment lines, with durable activity in heavily pretreated patients
- Relapsed/refractory cohort: 83.0% ORR and 22.1-month median PFS after 22.4-month follow-up
- Second-line, BCL2-inhibitor-naïve cohort: 92.9% ORR among 14 evaluable patients
- BTK-inhibitor-naïve cohort: 84.2% ORR among 19 evaluable patients, including treatment-naïve patients
- Safety remained favorable across 142 patients, with 5.6% discontinuing treatment due to adverse events and no treatment-related Grade 5 events
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nurix Therapeutics, Inc. 8-K filings
Get the next NRIX 8-K as it lands
Follow NRIX for push alerts, or ask the research agent what this filing means.